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Abstract
Mutations in human Gli-similar (GLIS) 3 protein cause neonatal diabetes. The GLIS3 gene region has also been identified as a
susceptibility risk locus for both type 1 and type 2 diabetes. GLIS3 plays a role in the generation of pancreatic beta cells and
in insulin gene expression, but there is no information on the role of this gene on beta cell viability and/or susceptibility to
immune- and metabolic-induced stress. GLIS3 knockdown (KD) in INS-1E cells, primary FACS-purified rat beta cells, and
human islet cells decreased expression of MafA, Ins2, and Glut2 and inhibited glucose oxidation and insulin secretion,
confirming the role of this transcription factor for the beta cell differentiated phenotype. GLIS3 KD increased beta cell
apoptosis basally and sensitized the cells to death induced by pro-inflammatory cytokines (interleukin 1b + interferon-c) or
palmitate, agents that may contribute to beta cell loss in respectively type 1 and 2 diabetes. The increased cell death was
due to activation of the intrinsic (mitochondrial) pathway of apoptosis, as indicated by cytochrome c release to the cytosol,
Bax translocation to the mitochondria and activation of caspases 9 and 3. Analysis of the pathways implicated in beta cell
apoptosis following GLIS3 KD indicated modulation of alternative splicing of the pro-apoptotic BH3-only protein Bim,
favouring expression of the pro-death variant BimS via inhibition of the splicing factor SRp55. KD of Bim abrogated the pro-
apoptotic effect of GLIS3 loss of function alone or in combination with cytokines or palmitate. The present data suggest that
altered expression of the candidate gene GLIS3 may contribute to both type 1 and 2 type diabetes by favouring beta cell
apoptosis. This is mediated by alternative splicing of the pro-apoptotic protein Bim and exacerbated formation of the most
pro-apoptotic variant BimS.
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Introduction
The Kruppel-like zinc finger protein Gli-similar (GLIS) 3 plays
a critical role in pancreatic development, and loss-of-function
mutations in this transcription factor lead to a syndrome
characterized by neonatal diabetes, hypothyroidism and other
congenital dysfunctions [1,2]. Genome-wide association studies in
large numbers of individuals with type 1 (T1D) or type 2 (T2D)
diabetes indicated that common variants near GLIS3 gene are
associated with both forms of diabetes [3–7], making GLIS3 one of
the few candidate genes for both T1D and T2D. It remains to be
proven, however, that susceptibility alleles for T1D and T2D
actually decrease expression of GLIS3 in pancreatic beta cells.
GLIS3 is also implicated in the regulation of human fasting
glucose and insulin [4,8] and glucose-stimulated insulin release [5],
suggesting a key role for the transcription factor in human beta cell
development/function.
GLIS3 deficient mice have a major decrease in beta cell mass
and develop neonatal diabetes [9,10]. These mice also have
decreased expression of several key transcription factors required
for the endocrine development of the pancreas, i.e. Neurogenin3,
NeuroD1, MafA and Pdx1 [9,10]. Moreover, conditional knock-
out of GLIS3 in adult mice causes defective insulin secretion and
increase susceptibility to high fat diet-induced diabetes [11]. In vitro
knockdown (KD) or overexpression of GLIS3 in rat insulinoma
832/13 cells showed that the transcription factor binds to a cis-
acting element in the rat insulin 2 (Ins2), modulating its
transcriptional activity [12]. GLIS3 also synergizes with the beta
cell transcription factors Pdx1, MafA and NeuroD1, increasing
insulin promoter activity, besides directly regulating the expression
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of MafA (another important inducer of the insulin promoter) [12].
These observations suggest that GLIS3 plays an important role for
the development of mature pancreatic beta cells and for the
transcription of its key hormone insulin.
There is, however, little information on the role of GLIS3 in
beta cell susceptibility to immune- or metabolic-induced apoptosis
and little data on its impact on adult beta cells. Beta cell apoptosis
contributes to the two main forms of diabetes [13,14]. Diabetes
candidate genes expressed in beta cells may have a major impact
on cell survival/function in T2D [15,16,17] and T1D [18–22] and
in the local inflammatory responses leading to insulitis and chronic
autoimmunity in T1D [19,21,23].
We have presently developed an in vitro model of GLIS3
deficiency in beta cells by using siRNAs targeting different regions
of the GLIS3 mRNA. GLIS3 KD increased beta cell apoptosis
under basal condition and sensitized cells to death induced by
interleukin 1b (IL-1b) + interferon-c (IFN-c) or palmitate, agents
that may contribute to beta cell loss in respectively T1D and T2D.
This increase in apoptosis was secondary to the activation of the
intrinsic pathway of apoptosis through alternative splicing of the
pro-apoptotic BH3-only protein Bim at least in part via inhibition
of the splicing factor SRp55. The present data provide the first
indication that a candidate gene for diabetes may modify
alternative splicing and thus hamper beta cell survival.
Results
GLIS3 KD in INS-1E cells (Figure 1A–1E) significantly
decreased key transcription factors for the maintenance of the
beta cell phenotype, namely MafA and Pdx1, the glucose
transporter Glut2 and INS2. These observations were reproduced
using a second siRNA targeting GLIS3 (Figure S1A and S1B), and
were confirmed in primary rat beta cells, where a 50% KD of
GLIS3 led to a decrease in INS2 expression and a trend for
decreased Glut2 expression (Figure 1F–1H). These changes in gene
expression by GLIS3 KD had a functional impact, with decreased
basal and glucose-stimulated glucose metabolism and of glucose
+/2 forskolin-induced insulin release in INS-1E cells (Figure 1K–
1L) and a 25% decrease in insulin accumulation in the medium of
human islets transfected with GLIS3 siRNA, as compared to
controls (Figure 1J).
We next evaluated whether GLIS3 KD affects beta cell viability
under basal condition or following exposure to stress signals that
may be relevant for type 1 diabetes, namely the pro-inflammatory
cytokines IL-1b + IFN-c or the viral by-product double stranded
RNA (dsRNA) [18,19,21], tested here as the synthetic analog PIC,
or for type 2 diabetes, namely the free fatty acids oleate and
palmitate [13]. GLIS3 KD by two independent siRNAs increased
basal and cytokine-induced apoptosis in INS-1E cells (Figure 2B,
Figure S1C, Figure S2A and S2B). Importantly, GLIS3 KD by two
independent siRNAs also augmented apoptosis in human islet
cells, under both basal condition and following exposure to IL-1b
+ IFN-c (Figure 2C and 2D, Figure S1D and S1E). The KD of
GLIS3 (Figure 2E and 2G) also sensitized INS-1E cells to apoptosis
induced by PIC (Figure 2F), oleate and palmitate (Figure 2H).
Thus, even a partial decrease in GLIS3 expression, as may be the
case in some of the diabetes-predisposing gene polymorphisms,
enhances beta cell sensitivity to basal, immune- or metabolic
stress-induced apoptosis. In a mirror image of these experiments,
GLIS3 overexpression using an adenoviral vector (Figure S3A) lead
to increase MafA expression (Figure S3B) and decreased by.50%
cytokine-induced apoptosis in INS-1E cells (Figure S3C). Apop-
tosis secondary to GLIS3 KD and exposure to pro-inflammatory
cytokines was mediated by the intrinsic (mitochondrial) pathway of
apoptosis, as suggested by increased cleavage of caspases 9 and 3
(Figure 3A; densitometry in Figure S2A and S2B), cytochrome c
release to the cytosol (Figure 3B; densitometry in Figure S2C) and
Bax translocation to the mitochondria (Figure 3C).
A possible mechanism for cytokine-induced apoptosis in beta
cells is increased nitric oxide production and consequent
endoplasmic reticulum (ER) stress and Chop activation [24,25].
GLIS3 KD, however, did not increase nitric oxide production
(Figure S4A) or Chop expression (Figure S4B), making it unlikely
that these are relevant mechanisms for beta cell apoptosis
following GLIS3 inhibition. Interestingly, GLIS3 KD led to a
decrease in Chop expression under basal condition or at some time
points following cytokine exposure. Beta cells express markers of
ER stress even under basal condition, probably due to the high
load on the ER caused by physiological and fluctuating insulin
production [26]. It is conceivable that the decrease in Ins2 mRNA
expression observed in GLIS3 KD cells (Figure 1D) contributes to
the observed decrease in Chop expression.
Beta cell survival is critically dependent on the balance between
anti- and pro-apoptotic Bcl-2 proteins [27]. To examine whether
GLIS3 modulates these proteins we measured expression of two
key anti-apoptotic proteins, namely Bcl-2 and Bcl-xL. GLIS3
inhibition did not affect Bcl-2 and Bcl-xL expression under basal
condition or following exposure to cytokines (Figure 4), and
neither was there a change in a third anti-apoptotic protein,
namely Mcl-1 (data not shown). We next examined the pro-
apoptotic BH3-only proteins DP5 and PUMA. These proteins
have previously been shown to contribute to IL-1b + IFN-c-
mediated beta cell apoptosis [28,29], but their expression was not
increased by GLIS3 KD (Figure S4C and S4D). If anything, there
was a decrease in PUMA expression at some time points.
Another important mediator of cytokine-induced beta cell
apoptosis is the BH3-only protein Bim. Previous studies from our
group have shown that STAT-1-induced Bim expression [30,31]
and JNK-induced Bim phosphorylation on serine 65 [20]
contribute to beta cell apoptosis. GLIS3 KD (Figure 5A) increased
basal Bim mRNA expression and led to a mild increase in its
expression following cytokine treatment at 2 and 8 h, with a
decrease after 16 and 24 h (Figure 5B). This was independent of
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Pancreatic beta cell dysfunction and death is a central
event in the pathogenesis of diabetes. Genome-wide
association studies have identified a large number of
associations between specific loci and the two main forms
of diabetes, namely type 1 and type 2 diabetes, but the
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favouring beta cell apoptosis. This is mediated by the
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multiple ways, leading to the generation of several
proteins by a single gene) of the pro-apoptotic protein
Bim, which favours formation of the most pro-apoptotic
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susceptibility gene for diabetes may contribute to disease
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STAT-1 activation, since GLIS3 KD did not modify total or
phospho-STAT1 expression following exposure to IL-1b + IFN-c
for 0.25–24 h (data not shown). Bim has three main isoforms
generated by alternative splicing, namely BimEL, BimL, and BimS
[32]. Western blot showed a preferential and nearly 2-fold increase
in the expression of BimS in GLIS3 KD cells both before and after
exposure to cytokines (Figure 5C; the blots are quantified in
Figure 5D). There was a less marked increase in BimEL and BimL
at some of the time points following cytokine exposure (Figure 5C;
densitometry in Figure S5A and S5B). The BimS up-regulation
seems to be secondary to GLIS3-modulated alternative splicing,
since GLIS3 KD induced a nearly 2-fold increase in BimS mRNA
expression basally and following cytokine exposure (Figure 5E),
with only a minor and transient increase in BimEL and BimL
mRNA (at 2–8 h of cytokine treatment) which was followed by a
significant decrease after 16 and 24 h (Figure S5C and S5D).
Importantly, these findings were reproduced in human islets,
where KD of GLIS3 led to nearly 50% increase of BimS (Figure 5F)
with no significant increase in the other two splice variants (Figure
S5E and S5F). In INS-1E cells exposed to palmitate, there was also
a significant increase in BimS expression (Figure 5G) and less
marked changes in BimEL and BimL (Figure S5G and S5H). The
mirror image was seen in gain-of-function experiments: adenoviral
GLIS3 overexpression (Figure S7A) decreased BimS expression and
caspase 3 cleavage (Figure S7B). The decreased caspase 3
activation corroborates the finding that GLIS3 overexpression
protects against cytokine-induced apoptosis (Figure S3C), probably
via inhibition of BimS (Figure S7B).
We have previously shown that this Bim siRNA markedly
decreases expression of the three splice variants of Bim in cytokine-
treated INS-1E cells [30]. In both INS-1E cells, primary beta cells
and human islet cells Bim depletion by .50% (P,0.05) (Figure
S6A, S6B and data not shown) abrogated the basal increase in
apoptosis observed following GLIS3 KD (Figure 6A, 6B and 6C).
Interestingly, while Bim depletion protected human islet cells
against apoptosis (Figure 6C), it failed to prevent the decrease in
insulin secretion secondary to GLIS3 KD (data not shown),
indicating dissociation between the functional and pro-apoptotic
effects of GLIS3 KD. Bim KD also partially prevented the increase
in cell death induced by GLIS3 KD + cytokines (Figure 6A, 6B and
6C). These observations were confirmed with a second siRNA
(Figure 6D) that induced a preferential inhibition of BimS (7164%
inhibition of BimS, P,0.001). To examine whether this beneficial
effect of Bim KD was restricted to cytokines, we performed double
KD for GLIS3 and Bim and then exposed the cells to palmitate
(Figure 6E). Palmitate treatment also preferentially increased
expression of BimS in INS-1E cells (Figure 5G, Figure S5G and
S5H). Bim KD had only a minor protective effect against palmitate
alone, in agreement with recent data suggesting that DP5 and
PUMA are the main mediators of palmitate-induced beta cell
apoptosis [33], but it abrogated the additive effect of GLIS3 KD
upon palmitate exposure, decreasing cell death to the levels
observed with palmitate alone (Figure 6E).
To address the mechanisms by which GLIS3 affect Bim
splicing, we examined the potential role of Pnn and SRp55, two
splicing factors described in other tissues as potential regulators of
Bim splicing [34,35] and detected as present and modified by
cytokines in human islets exposed to cytokines [21]. Pnn
expression was not modified by GLIS3 KD (data not shown).
On the other hand, GLIS3 KD decreased protein expression of
SRp55 in INS-1E cells (Figure 7A) (43%68% inhibition of SRp55
protein expression, p,0.05, n = 7), while GLIS3 overexpression
augmented SRp55 expression basally and following cytokine
exposure (Figure S7B). To assess the functional impact of
decreased expression of SRp55, we inhibited it with two specific
siRNAs (Figure 7B). After KD of SRp55, there was a significant
increase of BimS expression under both basal condition and
following cytokine treatment (Figure 7C). We next evaluated
whether SRp55 KD affects beta cell viability and observed an
increase in apoptosis under basal condition and following cytokine
exposure (Figure 7D) indicating a relevant role of SRp55 in
viability. Double KD of SRp55 and BimS (71%64% inhibition of
BimS, p,0.001) counteracted the increase in apoptosis caused by
SRp55 KD (Figure 7D), suggesting a role for this splicing regulator
in the downstream effects of GLIS3 (Figure 7E).
cAMP generators have been previously shown to protect beta
cells against both cytokine- and palmitate-induced apoptosis [36–
39], and we evaluated whether forskolin could prevent beta cell
apoptosis following GLIS3 KD. Interestingly, forskolin nearly
completely prevented the basal increase in apoptosis following
GLIS3 KD (Figure 8A), which was accompanied by a significant
decrease in the expression of BimS but not BimEL or BimL
(Figure 8B and 8C). In cytokine-treated GLIS3 KD deficient cells
forskolin induced only a mild and partial protection, which was
paralleled by a progressive restoration of BimS expression
(Figure 8B and 8C).
Discussion
Genome-wide association studies have allowed the identification
of a large number of associations between specific loci and T1D or
T2D. The mechanisms by which most of these candidate genes
predispose to diabetes remain to be clarified. This emphasizes the
need for detailed studies on the function of candidate genes in the
key tissues involved in the development of diabetes. Taking into
account the central role for beta cell failure in both T1D and T2D
[13], it is of particular relevance to clarify the potential impact of
these ‘‘diabetes genes’’ on pancreatic beta cell dysfunction and
death.
There is little convincing genetic link between T1D and T2D to
date [40–42], with the possible exception of Latent Autoimmune
Diabetes in Adult (LADA), a particular form of diabetes that has
been reported to share some susceptibility risk factors from both
T1D and T2D [43]. To our knowledge the GLIS3 locus is the only
one showing association with genome-wide significance for both
T1D, T2D or glucose metabolism traits in non-diabetic subjects,
adults or children and adolescents, and in population-based
cohorts [3–8]. GLIS3 is the single gene located within the
confidence interval of the region of association with T1D [3],
and the SNPs that have been reported to be associated with T1D,
T2D and T2D-related traits are all in very strong linkage
disequilibrium (LD) to each other (pairwise correlation coefficient
Figure 1. GLIS3 regulates the differentiated beta cell phenotype. INS-1E cells, primary FACS-purified rat beta cells and human islet cells were
transfected with control or GLIS3 siRNA (siCTL and siGLIS3, respectively; siGLIS3 here and below refers always to the GLIS3 siRNA#1; different siRNAs
were used for rat and human cells as shown in Table S1). After 48 h, cells were used for real-time PCR analyses in INS-1E (A–E), primary rat beta cells
(F–H), human islet cells (I) or functional studies (J–L). Results are means 6 SEM corrected by the housekeeping genes GAPDH or b-actin (n = 4–5); (J)
medium insulin accumulation of dispersed human islet cells; (K) glucose metabolism of INS-1E cells exposed to 1 or 10 mM glucose after GLIS3 KD
(n = 6); (L) insulin secretion in INS-1E cells treated with 1 mM glucose, 10 mM glucose or 10 mM glucose plus forskolin (20 mM) after GLIS3 KD (n= 5).
* P,0.05, ** P,0.01 and *** P,0.001 vs. siCTL by paired t-test.
doi:10.1371/journal.pgen.1003532.g001
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r2 of 0.95 to 1.0 between the strongest associated SNPs for the key
studies [3,4,6,7,44]), supporting the hypothesis that a unique
variant near GLIS3 may be responsible for all the reported
associations with these common diabetes and related traits.
Furthermore, a review of all the published genetic studies and
available data on T1D, T2D and T2D-related traits indicated that
Figure 2. GLIS3 KD potentiates apoptosis induced by cytokines, PIC, and FFAs. Following transfection with siCTL and siGLIS3 as in Figure 1,
INS-1E cells (A, B, E–H) and human islet cells (C, D) were exposed to cytokines (A, B, C, D) (n = 4–7), PIC (E, F) (n = 7), oleate or palmitate (G, H) (n = 5).
After 24 h GLIS3 mRNA expression and apoptosis were evaluated. Results are means 6 SEM. * P,0.05, ** P,0.01 or *** P,0.001 vs. siCTL by paired
t-test.
doi:10.1371/journal.pgen.1003532.g002
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the orientation of association is concordant between all these traits
(C. Julier, unpublished observations), with the same allele
associated with increased risk of T1D, increased risk of T2D,
increased fasting glucose, decreased fasting insulin level, decreased
HOMA-B and glucose stimulated insulin release (nominal P-values
for association with these traits,1023 [4,5]), suggesting the role of
a shared mechanism between both forms of diabetes.
Pancreatic islets from T2D patients have a nearly 50% decrease
in GLIS3 mRNA expression as compared to islets obtained from
non-diabetic subjects (P,0.001; data re-calculated from [45] and
confirmed by RT-PCR analysis of whole islets and FACS-purified
human beta cells; Bugliani M, Marselli L and Marchetti P,
unpublished data), but it remains to be determined whether this is
a direct effect of the risk alleles on GLIS3 expression or secondary
to chronic exposure to high glucose levels. Similarly, GLIS3 was
found to be one of the most differentially expressed genes between
beta cells from T2D and non-diabetic subjects [46]. The fact that
recessive loss-of-function mutations in GLIS3 cause severe neonatal
diabetes in humans [1] and in transgenic mouse models [9,10],
secondary to a major decrease in beta cell mass, suggests that this
transcription factor is necessary for beta cell development and
differentiation. Together, these genetic and functional observa-
tions indicate that GLIS3 itself is the susceptibility gene responsible
for the observed associations with T1D, T2D and T2D-related
traits. The region strongly associated with T1D as defined by
Barrett et al. [3] maps to the 59 region of the GLIS3 long transcript,
which is pancreas and thyroid specific [1] and includes the first
exons and corresponding promoter region. Of note, all the SNPs
in LD with diabetes and associated SNPs are non-coding. This
suggests that the responsible variant affects the regulation of GLIS3
expression in pancreatic beta cells, most likely through a reduction
of GLIS3 expression predisposing to T1D and T2D. It is thus
important to understand whether these milder phenotypes affect
the resistance of adult beta cells to challenges provided by
immune-, viral- or metabolic-mediated stress. These stresses may
cross talk with candidate genes for T1D and T2D.
Our present observations suggest that a relatively mild
reduction of GLIS3 gene expression in beta cells by two
independent siRNAs decreases expression of Pdx1, MafA, Ins2
and Glut2 and inhibit glucose oxidation and glucose-induced
insulin secretion. These findings are in line with evidence obtained
in foetal, neonatal or adult mouse beta cells [9,11], and suggest a
key role for GLIS3 in maintaining the beta cell differentiated
phenotype.
Of particular interest in the context of diabetes is the
observation that GLIS3 KD increases rat beta cell apoptosis under
basal condition and sensitizes the cells to death induced by pro-
inflammatory cytokines (IL-1b + IFN-c), the viral by-product
dsRNA, and the free fatty acids oleate and palmitate, while GLIS3
up-regulation protects against cytokine-induced apoptosis (present
data). GLIS3 KD also increases apoptosis of human islet cells
under both basal condition and following exposure to IL-1b +
IFN-c. This broad range of sensitization to pro-apoptotic stimuli
by GLIS3 KD suggests that GLIS3, besides contributing to
maintain beta cell function, provides signals required for
preservation of cell viability. In line with these observations,
suppression of Pdx1, a key transcription factor for the maintenance
of the differentiated phenotype of beta cells, triggers beta cell death
via dissipation of the mitochondrial inner membrane electrochem-
ical gradient Deltapsi(m) [47]. GLIS3 KD also contributes to beta
cell apoptosis via a mitochondrial phenomenon, namely triggering
of the intrinsic pathway of apoptosis as a result of the activation of
the BH3-only protein Bim (see below). Decreased Pdx1 expression
sensitizes pancreatic beta cells to ER stress [48], but this is not the
case for GLIS3 KD, as indicated by normal expression of Chop
(present findings) and other ER stress markers (data not shown).
The increase in cell death in GLIS3 deficient cells is secondary to
activation of the intrinsic pathway of apoptosis, as indicated by
Cytochrome c release to the cytosol, Bax translocation to the
mitochondria and activation of caspases 9 and 3. A detailed
analysis of the upstream pathways implicated in GLIS3 KD-
induced beta cell apoptosis indicated modulation of alternative
splicing of the pro-apoptotic BH3-only protein Bim, favouring
expression of the most pro-apoptotic splice variant of Bim, namely
BimS [49,50]. In agreement with these observations, Bim depletion
abrogated the pro-apoptotic effects of GLIS3 KD alone or in
combination with pro-inflammatory cytokines or palmitate. Bim
can bind to and inhibit most anti-apoptotic Bcl-2 proteins, besides
directly activating the pro-apoptotic protein Bax [51]. Important-
ly, Bim contributes to cytokine- [20,30], virus- [23] and high
glucose-induced [52] pancreatic beta cell apoptosis. Previous
observations in pancreatic beta cells indicated that Bim can be
regulated by cytokines at the transcriptional [30,53] or phosphor-
ylation [20] level. The present study is the first to show regulation
of Bim function in beta cells by changes in splicing. There are three
main isoforms of Bim, namely BimEL, BimL, and BimS that are
generated by alternative splicing [32]. BimEL and BimL have a
binding site for the dynein light chain 1 which decreases their pro-
apoptotic activity via sequestration to the cytoskeleton [32,54],
while BimS is free to exert its potent pro-apoptotic activity [49,50].
Alternative splicing affects more than 90% of human genes [55].
It generates enormous proteome diversity, and may have a major
impact on cell survival, exposure of novel antigenic epitopes,
alteration of surface location of antigens and posttranslational
modifications. There is a growing interest in the role of alternative
splicing in several autoimmune diseases [56], but nearly nothing is
known on its role in pancreatic beta cell dysfunction and death in
diabetes. We have recently shown that beta cell exposure to pro-
inflammatory cytokines modifies alternative splicing of hundreds
of expressed genes and affects expression of more than 50 splicing-
regulating proteins [21,57]. Palmitate also modifies alternative
splicing of a different group of genes in human islets (Cnop M,
Sammeth M, Bottu G and Eizirik DL, unpublished data). The
present observations provide the first indication that a candidate
gene for diabetes may act by regulating alternative splicing. This
effect of GLIS3 KD is mediated, at least in part, via down
regulation of the splicing factor SRp55 (Figure 7). This was
confirmed by the reverse experiment, i.e. GLIS3 overexpression
Figure 3. GLIS3 KD potentiates cytokine-induced beta cell death via the mitochondrial pathway of apoptosis. INS-1E cells were
transfected with siCTL or siGLIS3 (siGLIS3#1 and #2) and then exposed or not to cytokines. After 24 h cells were used for immunoblotting or
immunofluorescence analysis. (A) Cleaved caspases-9 and -3. Blots are representative of 4 independent experiments. a-Tubulin was used as a control
for protein loading in the different lanes; (B) cytochrome c release from the mitochondria to the cytosol. Blots are representative of 4 independent
experiments. AIF and COX IV are used as mitochondrial markers, confirming adequate sub-cellular fractionation; (C) BAX localization was studied by
immunocytochemistry. Nuclear morphology is shown by Hoechst staining. Arrows indicate BAX co-localization with ATP synthase b (mitochondrial
marker). Images are representative of 4 independent experiments.
doi:10.1371/journal.pgen.1003532.g003
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Figure 4. GLIS3 KD does not change expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL. INS-1E cells were transfected with control
or GLIS3 siRNA. After 48 h cells were incubated with cytokines and collected at different time points for Western blot analyses. Representative blots
(A) and densitometry (B, C) of Bcl-2 and Bcl-xL protein expression normalized by the housekeeping protein a-tubulin. Results are means 6 SEM
(n = 4).
doi:10.1371/journal.pgen.1003532.g004
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induced SRp55 and prevented BimS production (Figure S7B). In
line with this, the inhibition of SRp55 led to an increase in BimS
expression and beta cell apoptosis (Figure 7). These results suggest
that GLIS3 regulates the expression of splicing factors and
consequently the splicing of their target genes. It remains to be
clarified whether this is a direct effect or a secondary phenomenon
via downstream regulation of other genes.
In conclusion, the present observations suggest that modifica-
tions in expression of the candidate gene GLIS3 may contribute to
both T1D and T2D by favouring beta cell apoptosis. This takes
place to a large extent via modified alternative splicing of the pro-
apoptotic protein Bim. Additional studies are now required to
characterize this new avenue for functional studies on candidate
genes for diabetes, namely their cross-talk with alternative splicing
and other processes regulating generation of gene/protein
diversity.
Materials and Methods
Ethics statement
Human islet collection and handling were approved by the local
Ethical Committee in Pisa, Italy. Wistar rats were used according
to the rules of the Belgian Regulations for Animal Care with
approval of the Ethical Committee for Animal Experiments of the
ULB.
Culture of INS-1E cells, FACS-purified rat beta cells, and
human islet cells
INS-1E cells (kindly provided by C. Wollheim, Centre Medical
Universitaire, Geneva, Switzerland) at passages 60–72 were
cultured in RPMI 1640 GlutaMAX-I medium, supplemented
with 5% heat-inactivated foetal bovine serum (FBS), 50 units/ml
penicillin, 50 mg/ml streptomycin, 10 mM HEPES, 1 mM Na-
pyruvate, and 50 mM 2-mercaptoethanol in a humidified atmo-
sphere at 37uC and 5% CO2.
Isolated pancreatic islets of male Wistar rats (Charles River
Laboratories, Brussels, Belgium), housed following the guidelines
of Belgian Regulations for Animal Care, were dispersed and beta
cells purified by autofluorescence-activated cell sorting (FACSAria,
BD Bioscience, San Jose, CA, USA) [58,59]. Beta cells (9362%
purity; n = 6) were cultured in Ham’s F-10 medium containing
10 mM glucose, 2 mM glutamine, 50 mM 3-isobutyl-L-methyl-
xanthine, 0.5% fatty acid-free bovine serum albumin (BSA)
(Roche, Indianapolis, IN, USA), 5% FBS, 50 units/ml penicillin,
and 50 mg/ml streptomycin [59]. The same medium but without
FBS was used during cytokine exposure.
Human islet cells from 8 non-diabetic donors (age 6665 years,
five men/three women, body mass index 25.760.9 Kg/m2) were
isolated in Pisa, with the approval of the Ethics Committee of the
University of Pisa. Islets were isolated by enzymatic digestion, and
density-gradient purification [60]. They were then cultured in
M199 medium containing 5.5 mM glucose and shipped to
Brussels, Belgium within 1–5 days of isolation. After overnight
recovery in Ham’s F-10 containing 6.1 mM glucose, 10% FBS,
2 mM GlutaMAX, 50 mM 3-isobutyl-1-methylxanthine, 1% BSA,
50 U/ml penicillin and 50 mg/ml streptomycin, islets were
dispersed, transfected with siCTL, siGLIS3, siBim or siGLIS3/
siBim and exposed or not to cytokines for 24 h. The same medium
but without FBS was used during cytokine exposure. The
percentage of beta cells in the dispersed islet preparations, as
determined by immunohistochemistry for insulin [37], was
4866%.
RNA interference
The siRNAs used in the study are described in Table S1. The
optimal concentration of siRNA used for cell transfection (30 nM)
was established previously [61]. Cells were transfected using the
Lipofectamine RNAiMAX lipid reagent (Invitrogen, Carlsbad,
CA, USA) as previously described [31]. Allstars Negative Control
siRNA (Qiagen, Venlo, the Netherlands) was used as negative
control (siCTL). siCTL does not affect beta cell gene expression or
insulin release, as compared with nontransfected cells [31,61,62].
Beta cells transfected with siRNAs were used for experiments 24–
48 h after transfection.
Generation of recombinant adenovirus and cell infection
To express GLIS3 in insulin-secreting cells, we obtained from
SIRION Biotech (Munich, Germany) a recombinant adenovirus
comprising fragments of the mouse GLIS3 mRNA (GenBank:
NM_175459).
The murine GLIS3 coding region was amplified by PCR from
cDNA clone BC167165 purchased from Source Bioscience
(Berlin, Germany) and was cloned via Nhe1 and EcoRV into
the shuttle vector pO6-A5-CMV to give pO6-A5-CMV-GLIS3.
The CMV-GLIS3-SV40-pA region of pO6-A5-CMV-GLIS3 was
then transferred via recombination in a BAC vector containing the
genome of a replication deficient Ad5-based vector deleted in E1/
E3 genes. Presence and correctness of the GLIS3-ORF in the
resulting BAC-vector BA5-CMV-GLIS3 was confirmed by DNA-
sequencing.
An adenovirus expressing the luciferase protein (Ad-LUC) was
used as control [63]. INS-1E cells were infected as previously
described [63].
Cell treatment
The cytokine concentrations used were based on previous dose-
response experiments performed by our group [64,65] and were
10 units/ml or 50 units/ml of recombinant human IL-1b for INS-
1E cells or primary rat beta cells/human islet cells, respectively (a
kind gift from Dr. C.W. Reinolds, National Cancer Institute,
Bethesda, MD-USA) and 100 units/ml or 500 units/ml of
recombinant rat IFN-c for INS-1E cells and primary rat beta
cells or 1000 units/ml of recombinant human IFN-c for human
islet cells (R&D Systems, Abingdon, UK). Culture supernatants
from cytokine-treated cells were collected for nitrite determination
(nitrite is a stable product of NO oxidation) at OD540 nm using
the Griess method. The synthetic dsRNA polyinosinic-polycy-
tidylic acid (PIC; Sigma, St Louis, LO, USA) was used at the final
Figure 5. GLIS3 KD induces Bim expression in INS-1E and human dispersed islet cells. INS-1E (A–E, G) and human dispersed islet cells (F)
were transfected with control or GLIS3 siRNA. After 48 h human islets were collected for real-time analysis and INS-1E cells were incubated with
cytokines (A–E) or palmitate (G) and collected at different time points for Western blot or real-time PCR analyses. mRNA expression of GLIS3 (A) and
Bim (B) after GLIS3 KD; (C) representative blot (n = 4) of the expression of the protein isoforms BimEL (extra-large), BimL (large) and BimS (small); (D)
densitometry of BimS expression normalized by the housekeeping protein a-tubulin; (E, F and G) mRNA expression of BimS after GLIS3 KD in INS-1E
cells and exposure to cytokines (E) or palmitate (G) or in human dispersed islet cells under basal conditions (F). Results are means 6 SEM (n= 4).
* P,0.05, ** P,0.01 and *** P,0.001 vs. siCTL. Paired t-test.
doi:10.1371/journal.pgen.1003532.g005
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concentration of 1 mg/ml [19]. Cellular transfection with PIC was
made as described for siRNA, with the difference that Lipofecta-
mine 2000 was used instead of Lipofectamine RNAiMAX [19].
Oleate and palmitate (sodium salt, Sigma, Bornem, Belgium) were
dissolved in 90% (vol./vol.) ethanol and diluted 1:100 to a final
concentration of 0.5 mM in the presence of 1% charcoal-absorbed
BSA, corresponding to a free fatty acid/BSA ratio of 3.4 [66,67].
Forskolin was diluted in DMSO and used at final concentration of
20 mM (Sigma).
mRNA extraction and real-time PCR
mRNA was extracted and reverse transcribed as described [59].
Expression of target genes was determined by real-time PCR using
SYBR Green [59,68] and comparison with a standard curve [69].
Expression values were corrected by the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for INS-1E
and primary rat beta cells and b-actin for human islet cells. GAPDH
or b-actin expression is not modified under the present experi-
mental conditions [18,66,70]. Primer sequences are described in
Table S2. Primers forMafA, Pdx1, INS2, Glut2, Chop, Dp5 and Puma
were described previously [53,71].
Glucose oxidation and insulin secretion
D-[U-14C] glucose (specific activity: 300 mCi/mM, concentra-
tion: 1 mCi/ml, Perkin Elmer, Waltham, MA, USA) was used to
evaluate glucose oxidation in control and GLIS3 KD cells exposed
to different glucose concentrations as described [72]. The rate of
glucose oxidation was expressed as pmol/120 min.105 cells.
For determination of insulin secretion, INS-1E cells were
incubated for 1 h in glucose-free RPMI GlutaMAX-I medium
and then incubated for 30 min in Krebs-Ringer solution. Cells were
then exposed to 1 mM, 10 mM or 10 mM glucose with forskolin
(20 mM) for 30 min. Insulin was measured in the supernatant by the
rat insulin ELISA kit (Mercodia, Uppsala, Sweden). Results were
normalized by the insulin content measured after cell lyses. Insulin
accumulation in the medium of cultured human islets was measured
by the human insulin ELISA kit (Mercodia, Uppsala, Sweden).
Assessment of cell viability
The percentage of viable, apoptotic and necrotic cells was
determined following 15 min of incubation with 5 mg/ml of the
DNA-binding dyes propidium iodide (PI, Sigma) and Hoechst
33342 (HO, Sigma). This method is quantitative and has been
validated for use in pancreatic beta cells and INS-1E cells by
comparison with electron microscopy, caspase-3 activation and
DNA laddering [18,59,66,73,74]. A minimum of 600 cells was
counted in each experimental condition. Viability was evaluated
by two independent observers, one of them unaware of sample
identity. The agreement between findings obtained by the two
observers was .90%. In some experiments apoptosis was
confirmed by Western blot analysis of cleaved caspase-9 and -3,
cytoplasmic cytochrome c release and BAX translocation to the
mitochondria.
Western blot and assessment of cytochrome c release
INS-1E cells were lysed in Laemmli buffer and equal amounts
of total protein were heated at 100uC for 5 min, resolved by
electrophoresis in 10–14% SDS-polyacrylamide gel and electro-
blotted onto nitrocellulose membranes. Immunodetection was
performed after overnight incubation with antibodies for cleaved
caspase 9 and 3 (Cell Signaling, Danvers, USA), Bcl-2 (Cell
Signaling, Danvers, USA), Bcl-xL antibody (Cell Signaling,
Danvers, USA), Bim and p-Bim antibodies (Cell Signaling,
Danvers, USA), SRp55 antibody (LifeSpan Biosciences), STAT1
and p-STAT1 antibodies (Cell Signaling). a-tubulin (Cell Signal-
ing) was used as the loading control. Membranes were then
exposed to 150 ng/ml secondary peroxidase-conjugated antibody
(anti IgG (H+L)-HRP, Invitrogen) for 2 h at room temperature
and visualized by chemiluminescence (SuperSignal, Pierce Bio-
technology, Rockford, IL, USA). Bands were detected by a LAS-
3000 CCD camera (Fujifilm, Tokyo, Japan). The densitometry of
the bands was evaluated using the Aida Analysis software (Raytest,
Straubenhardt, Germany).
For the assessment of cytochrome c release, INS-1E cells
harvested in cold PBS were centrifuged (500 g for 2 min) and
resuspended with 50 ml lysis buffer (75 mM NaCl, 1 mM
NaH2PO4, 8 mM Na2PO4, 250 mM sucrose, 21 mg/ml aprotinin,
1 mM PMSF and 0.8 mg/ml digitonin) and vortexed for 30 s. After
centrifugation (20,000 g for 1 min) the supernatant was collected
as the cytoplasmic fraction. The pellet was resuspended in 50 ml
lysis buffer containing 8 mg/ml digitonin, centrifuged (1 min at
20,000 g) and the supernatant collected as the mitochondrial
fraction [23,37]. Equal amounts of proteins were used for
Western-blotting with antibodies for cytochrome c (BD Bioscienc-
es) (cytoplasmic protein), apoptosis-inducing factor (AIF) and
cytochrome c oxidase (COX IV) (mitochondrial proteins) (Cell
Signaling). b-actin was used as the loading control.
Immunofluorescence
INS-1E cells were plated on polylysine-coated glass culture
slides (BD Biosciences). After transfection and treatment, cells were
fixed for 15 min in 4% paraformaldehyde, washed with PBS and
permeabilized in Triton X-100 0.1% for 5 min. Slides were then
blocked using 5% goat serum and incubated overnight at 4uC with
a Bax antibody (Santa Cruz Biotechnology) plus ATP synthase b
antibody (mitochondrial marker) (BD Biosciences). Cells were
washed with PBS and incubated for 1 h with the appropriate
Alexa fluor 488 or 555-conjugated antibodies (Invitrogen). Cells
were stained with Hoechst 33342, mounted and photographed
using fluorescence microscopy (Axio Imager, Carl Zeiss, Zaven-
tem, Belgium) [62].
Statistics
Data are presented as mean 6 SEM. Comparisons were
performed by two-tailed paired t-test or by ANOVA followed by
paired t-test with Bonferroni correction, as adequate.
A P value,0.05 was considered as statistically significant.
Figure 6. Bim mediates the potentiation of apoptosis in GLIS3-deficient cells. INS-1E cells (A, D and E), primary rat beta cells (B) and human
dispersed islet cells (C) transfected with control or GLIS3 siRNAs were exposed to cytokines (A, B, C and D) or palmitate (E) for 24 h. (A, B, C and E) cells
transfected with Bim siRNA (siBim); (D) cells transfected with a second Bim siRNA affecting preferentially BimS (siBimS). Apoptosis was then measured
using nuclear dyes. Results are means 6 SEM (n= 4–11). * P,0.05, ** P,0.01 or *** P,0.001 vs. siCTL without cytokines; ## P,0.01 or ### P,0.001
vs. siGLIS3; & P,0.05 or &&& P,0.001 vs. siBim; +++ P,0.001 vs. siGLIS3 + siBim; $ P,0.05, $$ P,0.01 or $$$ P,0.001 as indicated by the bars. ANOVA
followed by paired t-test with Bonferroni’s correction.
doi:10.1371/journal.pgen.1003532.g006
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Figure 7. GLIS3 KD decreases SRp55 expression in INS-1E cells. INS-1E cells were transfected with control, GLIS3 (A), SRp55 (B, C, D and E) and
BimS siRNAs (E). After 48 h cells were incubated with cytokines (C–E) for measuring apoptosis and collected at different time points for real-time PCR
analyses. (A) Representative blot of 2 independent experiments for SRp55 protein expression after GLIS3 KD (n = 7; densitometry is provided in
Results); (B) SRp55 mRNA expression after KD with two different siRNAs (SRp55#1 and SRp55#2); (C) mRNA expression of BimS after SRp55 KD and
exposure to cytokines; (D, E) apoptosis in cells transfected with SRp55 and/or a Bim siRNA targeting preferentially BimS (siBimS). Apoptosis was
measured using nuclear dyes. Results are means 6 SEM (n= 4–7). * P,0.05, ** P,0.01, *** P,0.001 vs. siCTL without cytokines @@@ P,0.001 vs.
siSRp55#1; ### P,0.001 vs. siSRp55#2; &&& P,0.001 vs. siBimS;
+++ P,0.001 vs. siSRp55 + siBimS; $ P,0.05 or $$ P,0.01 as indicated by the bars.
Paired t- test (7B and 7C) or ANOVA followed by paired t-test with Bonferroni’s correction (7D and 7E).
doi:10.1371/journal.pgen.1003532.g007
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Figure 8. Forskolin partially prevents apoptosis following GLIS3 KD. INS-1E cells transfected with control or GLIS3 siRNA were exposed to
forskolin (20 mM) and/or cytokines for 24 h. After this period apoptosis was measured using nuclear dyes. (A) Apoptosis induced by cytokine
treatment after siRNA transfection and forskolin exposure. Results are means 6 SEM (n= 6) * P,0.05 or *** P,0.001 vs. siCTL without forskolin;
### P,0.001 vs. siGLIS3 without forskolin; %%P,0.01 vs. siCTL with forskolin; @@@ P,0.001 vs. siGLIS3 with forskolin; $ P,0.05, $$ P,0.01, $$$ P,0.001
as indicated by the bars. ANOVA followed by paired t-test with Bonferroni’s correction; (B) Representative blot of BimEL, BimL and BimS protein
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Supporting Information
Figure S1 Confirmation of the effects of GLIS3 KD using
different siRNAs. INS-1E cells and human islet cells were
transfected with siCTL and different siRNAs for GLIS3 (#2)
and then exposed or not to cytokines. After 24 h cells were used
for real-time PCR analyses and apoptosis was measured. (A, D)
Confirmation of GLIS3 KD using a second siRNA for GLIS3 in
INS-1E cells (A) and human islet cells (D); (B) mRNA expression of
INS2 after GLIS3 KD in INS-1E cells; (C, E) apoptosis induced by
cytokine treatment of INS-1E cells or human islet cells after GLIS3
KD. Results are means 6 SEM (n= 4) * P,0.05, ** P,0.01 or
*** P,0.001 vs. siCTL by paired t-test.
(TIF)
Figure S2 GLIS3 KD induces caspase-9 and -3 cleavage and
Cytochrome c release. INS-1E cells were transfected with siCTL
and two different siRNAs for GLIS3 and then exposed or not to
cytokines for 24 h. (A, B) Densitometry of Western blots for
cleaved caspase-9 and -3, normalized by the housekeeping protein
a-tubulin (a representative blot is shown in Figure 3A). (C)
Densitometry analysis of the Western blots for cytochrome c
release from the mitochondria (a representative blot is shown in
Figure 3B). Results are means 6 SEM (n=4). * P,0.05,
** P,0.01 or *** P,0.001 vs. siCTL by paired t-test.
(TIF)
Figure S3 GLIS3 overexpression induces MafA expression and
prevents cytokine-induced apoptosis. INS-1E cells were infected or
not (NI, non-infected) with an adenoviral vector encoding GLIS3
(AdGLIS3) at MOIs ranging from 0.1 to 50, and then exposed or
not to cytokines for 24 h. (A) Confirmation of GLIS3 mRNA
overexpression by RT-PCR 24 h after infection. Results are means
6 SEM (n=4). * P,0.05 and ** P,0.01 vs. NI by paired t-test. (B)
Representative blot of 3 independent experiments for MafA protein
expression after infection with AdGLIS3 for 24 or 48 h. (C)
Apoptosis of INS-1E cells induced by a 24 h cytokine treatment
after infection with AdLUC (control adenoviral vector) or AdGLIS3
at MOI 10 for 24 h. Results are means6 SEM (n=4). *** P,0.001
vs. AdLUC without cytokines; ### P,0.001 vs. AdGLIS3 without
cytokines; $$$ P,0.001 as indicated by the bars. ANOVA followed
by paired t-test with Bonferroni’s correction.
(TIF)
Figure S4 GLIS3 KD does not increase nitric oxide production
or CHOP, DP5 and PUMA mRNA expression. INS-1E cells
transfected with siCTL or siGLIS3 were exposed or not to
cytokines and then used for nitrite measurement and real-time
PCR. (A) Nitrite measurement (reflecting nitric oxide production)
after GLIS3 KD and 24 h of cytokine treatment; (B–D) mRNA
expression of CHOP, DP5 and PUMA after GLIS3 KD and a time
course of cytokine exposure. Results are means 6 SEM corrected
by the housekeeping gene GAPDH (n = 4) * P,0.05 or ** P,0.01
vs. siCTL. Paired t-test.
(TIF)
Figure S5 Impact of GLIS3 KD on BimEL and BimL expression in
basal condition and after cytokine or palmitate treatment. After
48 h of control or GLIS3 siRNA, INS-1E cells were incubated
with cytokines (A–D) or palmitate (G–H) and collected at different
time points for Western blot and real-time PCR analyses. (A, B)
Densitometry of BimEL and BimL protein expression normalized
by a-tubulin; (C, D, G and H) mRNA expression of BimEL and
BimL normalized by the housekeeping gene GAPDH. (E and F)
mRNA expression in human islets of BimEL and BimL normalized
by the housekeeping gene b-actin after a 48 h of control or GLIS3
siRNA transfection. Results are means 6 SEM (n= 4). * P,0.05,
** P,0.01 or *** P,0.001 vs. siCTL by paired t-test.
(TIF)
Figure S6 Double KD of GLIS3 and Bim in primary rat beta
cells. FACS-purified rat beta cells were transfected with control,
GLIS3 or Bim siRNA. After 48 h cells were treated with cytokines
for 24 h. (A, B) mRNA expression of GLIS3 and BimS. Results are
means 6 SEM corrected by the housekeeping gene GAPDH
(n = 4). * P,0.05 vs. siCTL; $ P,0.05 or $$$ P,0.001 as indicated
by the bars. ANOVA followed by paired t-test with Bonferroni’s
correction.
(TIF)
Figure S7 GLIS3 overexpression down regulates BimS and
decreases cytokine-induced cleavage of caspase 3. INS-1E cells
were infected with AdLUC or AdGLIS3 at MOI 10 and 24 h later
exposed or not to cytokines for an additional 24 h. (A) mRNA
expression of GLIS3 normalized by GAPDH. Results are means 6
SEM (n= 4). (B) Representative blot of 2–4 independent
experiments for BimS, cleaved caspase-3 and SRp55 and the
housekeeping protein a-tubulin. $ P,0.05 as indicated by the bars.
Paired t-test.
(TIF)
Table S1 Sequences of siRNAs used to KD gene/protein
expression.
(DOC)
Table S2 Primer sequences and their respective PCR product
lengths. ST denotes standard PCR, RT denotes real time qPCR.
(DOC)
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